An interventional study of Intervention in Breast Cancer, sponsored by UNICANCER. Recruiting at 3 sites in 2 countries. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by UNICANCER · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by UNICANCER — 15 open to participants now, 27 under way, 7 of them phase 3. Breast Neoplasms · UNICANCER.
Among the 64 studies in Breast Neoplasms by UNICANCER, this one is the 9th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2026, is one of 14 with no phase, reaches primary completion later than 10 of the 26 other live ones, and was the 58th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 64 studies in Breast Neoplasms by UNICANCER are open now, in 9 countries. Recruiting first, the newest first:
UNICANCER · Sites in France
Ages 60+ · Women only
UNICANCER · Sites in Belgium, France, Greece and 4 more countries
Ages 35–45 · Women only
UNICANCER · Sites in France, Germany, Italy and 2 more countries
Ages 18+ · Women only
UNICANCER · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 74 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 29 · Phase 3 15
First in 1994; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,508 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 170 across the 59 interventional studies, 467 across the 4 observational. Of the 36 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
UNICANCER is the lead sponsor of 219 studies on the registry; 52 are open to participants now.
3 of the studies in Breast Neoplasms by UNICANCER that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03246841UNICANCERInvestigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. | 2026-12-30 |
| NCT07120087UNICANCEREvaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk. | 2026-12-31 |
| NCT03275311UNICANCEREvolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by UNICANCER, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer remains the most common cancer among women and a major cause of death despite advances in screening and treatment. Current screening programs are not personalized and are experiencing declining participation. A promising strategy for breast cancer control would be to implement risk-based prevention and early screening, targeting individuals at high risk of developing breast cancer, in order to improve chances of cure and reduce the need for more intensive treatments. The MyPeBS study was designed to assess whether personalized breast cancer screening (based on an individual's risk of developing breast cancer) is as effective as, or more effective than, current standard screening.
Lifestyle interventions involving changes in diet or physical activity, for example, have been shown to be effective in reducing the risk of developing breast cancer, whether low or high. The MyPeBS study evaluates personalized screening but offers limited information on breast cancer prevention. MyPREV is a project that aims to assess the feasibility and impact of a personalized online program on breast cancer risk reduction measures. This program is offered to women at high risk of developing breast cancer as part of the European MyPeBS screening study.
The main objective is to evaluate adherence to a personalized, online breast cancer prevention program focused on lifestyle and its acceptance among women at high or very high risk of developing cancer who participated in the MyPeBS study.
MyPREV is a prospective interventional cohort study. The study is based on an online educational, medical, and motivational intervention (webinar and online personalized clinical visit) dedicated to promoting and implementing lifestyle-based breast cancer risk-reduction measures among women identified in the MyPeBS trial as being at high or very high risk of breast cancer based on Polygenic risk score (PRS) and clinical scores. In MyPeBS, 34.4% of the women in the risk-based arm were estimated to be at high (33.03%) or very high (1.37%) to develop a breast cancer within 5 years.
The study MyPREV plans to invite 3016 women (1821 in France and 1195 in Italy for the sites CPO and ISPRO). The expected participation rate is 50%, so around 1507 women (910 in France and 597 in Italy for the sites CPO and ISPRO). The intervention consist of a virtual webinar and an online personalized clinical visit where the personalized prevention plan will be created.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Women who developed a breast cancer during their follow-up in the MyPeBS study
intervention
Behavioral: Intervention
Virual Webinar and online personalised clinical visit
Acceptance
To assess the acceptance of a full, targeted, online, educational and motivational intervention on breast cancer risk reduction measures among women who took part in MyPeBS and were identified to have a high or very high risk of breast cancer.
Time frame: From start of the inclusion up to the end of inclusions
Prevalence of risk reduction targets
Assess the prevalence of breast cancer risk reduction targets (potentially modifiable factors) among women willing to participate
Time frame: From start of the inclusion up to the end of inclusions
WCRF
Assess the participants' progress in modifying some of their behaviours according to the WCRF score at 3 months and 1 year
Time frame: At 3 months, 1 year
Strate-Trait Anxiety Inventory - State (STAI-S)
Evaluate patient characteristics (age, country, education level, professional occupation, Strate-Trait Anxiety Inventory \[STAI\] score at baseline in MyPeBS, level of breast cancer risk) associated with participation or non-participation in the proposed program and receipt of the proposed intervention
Time frame: At baseline
Subject knowledge and perception of knowledge
Evaluate the knowledge and perception of knowledge regarding breast cancer risk and risk reduction measures with a specific questionnaire
Time frame: At baseline, 1 year
Subject anxiety
Subject anxiety will be evaluated using the State-Trait Anxiety Inventory (STAI) questionaire
Time frame: At baseline, 1 year
Subject satisfaction
Subject satisfaction will be measured using a specific questionnaire.
Time frame: At baseline, 1 year
Levers and barriers for lifestyle modifications
Evaluate the prevalence of predefined or self-assessed potential levers and barriers for lifestyle modifications
Time frame: At 1 year
Plan to share: Yes — Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.
Access criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 10 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.